Access the full text.
Sign up today, get DeepDyve free for 14 days.
I Jawed, J Wilkerson, V Prasad, AG Duffy, T Fojo
Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis [published online June 25, 2015].
J. Bennouna, J. Sastre, D. Arnold, P. Österlund, R. Greil, E. Cutsem, R. Moos, J. Viéitez, O. Bouché, C. Borg, C. Steffens, V. Alonso-Orduña, C. Schlichting, I. Reyes-Rivera, B. Bendahmane, T. André, S. Kubicka (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.The Lancet. Oncology, 14 1
Q. Shi, A. Gramont, A. Grothey, J. Zalcberg, B. Chibaudel, H. Schmoll, M. Seymour, R. Adams, L. Saltz, R. Goldberg, C. Punt, J. Douillard, P. Hoff, J. Hecht, H. Hurwitz, E. Díaz-Rubio, R. Porschen, N. Tebbutt, C. Fuchs, J. Souglakos, A. Falcone, C. Tournigand, F. Kabbinavar, V. Heinemann, E. Cutsem, C. Bokemeyer, M. Buyse, D. Sargent (2015)
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 1
I. Jawed, J. Wilkerson, V. Prasad, A. Duffy, T. Fojo (2015)
Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.JAMA oncology, 1 6
S. Kopetz, G. Chang, M. Overman, C. Eng, D. Sargent, D. Larson, A. Grothey, J. Vauthey, D. Nagorney, R. McWilliams (2009)
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 22
D. Niedzwiecki, H. Lenz, F. Innocenti, M. Mahoney, B. O'Neil, J. Shaw, B. Polite, H. Hochster, J. Atkins, R. Goldberg, R. Mayer, R. Schilsky, M. Bertagnolli, C. Blanke (2014)
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 18_suppl
A. Gramont, M. Buyse, J. Abrahantes, T. Burzykowski, E. Quinaux, A. Cervantes, A. Figer, G. Lledo, M. Flesch, L. Mineur, E. Carola, P. Etienne, F. Rivera, I. Chirivella, N. Perez-staub, C. Louvet, T. André, I. Tabah-Fisch, C. Tournigand (2007)
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 22
Colorectal Cancer Survival Gains and Novel Regimens Original Investigation Research 13. Selvaggi F, Cuocolo A, Sciaudone G, Maurea S, 17. Cancer Research UK. Which treatment for 22. Sargent DJ, Wieand HS, Haller DG, et al. Giuliani A, Mainolfi C. FGD-PET in the follow-up of advanced bowel cancer. http://www Disease-free survival versus overall survival as a recurrent colorectal cancer. Colorectal Dis. 2003;5 .cancerresearchuk.org/about-cancer/type/bowel primary end point for adjuvant colon cancer (5):496-500. -cancer/treatment/types/which-treatment-for studies: individual patient data from 20,898 -advanced-bowel-cancer. Accessed May 1, 2015. patients on 18 randomized trials. J Clin Oncol. 2005; 14. Gearhart SL, Frassica D, Rosen R, Choti M, 23(34):8664-8670. Schulick R, Wahl R. Improved staging with 18. Memorial Sloan Kettering Cancer Center. pretreatment positron emission tomography/ Colorectal Cancer: Treatment for Metastases. https: 23. Buyse M, Burzykowski T, Michiels S, Carroll K. computed tomography in low rectal cancer. Ann //www.mskcc.org/cancer-care/adult/colorectal Individual- and trial-level surrogacy in colorectal Surg Oncol. 2006;13(3):397-404. /treatment-metastases. Accessed May 1, 2015. cancer. Stat Methods Med Res. 2008;17(5):467-475. 15. McDermott PW. Industry perspective on clinical 19. Bartlett EK, Simmons KD, Wachtel H, et al. The 24. Elston J, Taylor RS. Use of surrogate outcomes investigative sites: maximizing sponsor return on rise in metastasectomy across cancer types
JAMA Oncology – American Medical Association
Published: Sep 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.